Status:

COMPLETED

The Use of Silver Leaf Dressing in the Prevention of Radiotherapy Induced Skin Reactions

Lead Sponsor:

British Columbia Cancer Agency

Collaborating Sponsors:

Canadian Breast Cancer Foundation

Conditions:

Breast Neoplasms

Eligibility:

FEMALE

Phase:

PHASE3

Brief Summary

The hypothesis is that silver leaf nylon dressing reduces the percentage of patients developing brisk erythema and moist desquamation while undergoing whole breast radiotherapy. The secondary hypothes...

Detailed Description

Purpose: The delivery of whole breast radiotherapy to women with a deep inframammary fold frequently results in a marked skin reaction (brisk erythema and/or moist desquamation). The main aim of this ...

Eligibility Criteria

Inclusion

  • Women diagnosed with completely excised stage I or II invasive breast cancer, or DCIS, who have undergone breast-conserving surgery and are scheduled to undergo adjuvant breast radiotherapy will be eligible for this study if they are at increased risk of radiodermatitis at the inframammary fold due to breast size or shape (i.e at least 2cm of skin apposition at the inframammary fold, and/or brassiere cup size C or greater).
  • Patients undergoing nodal radiotherapy are eligible if criterion 1 is met
  • Patients undergoing boost radiotherapy are eligible if criterion 1 is met, but only if the boost volume does not include any part of the breast inferior to the nipple line
  • Patients may be entered into other local or national trials unless these involve an alteration to standard skin care or altered breast radiotherapy technique

Exclusion

  • inability to give informed consent
  • inability to comply with experimental arm of trial
  • failure of healing of the surgical scar or significant post-operative infection of the wound
  • prior radiotherapy to either breast or to the chest
  • presence of significant connective tissue disease (e.g. systemic sclerosis, systemic lupus erythematosis)
  • known radiation hypersensitivity phenotype (e.g. ataxia telangiectasia etc)
  • inability to return for assessment at one week following completion of radiotherapy
  • allergy to silver

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

End Date :

January 1 2007

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00207324

Start Date

January 1 2004

End Date

January 1 2007

Last Update

June 27 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

BC Cancer Agency

Vancouver, British Columbia, Canada, V5Z4E6